香港股市 已收市

Roche Holding AG (RHHVF)

Other OTC - Other OTC 延遲價格。貨幣為 USD。
加入追蹤清單
329.00-1.00 (-0.30%)
市場開市。 截至 09:30AM EDT。
全螢幕
交易股價資料並非來自所有市場
前收市價330.00
開市324.00
買盤0.00 x 0
賣出價0.00 x 0
今日波幅324.00 - 330.00
52 週波幅299.01 - 430.00
成交量65
平均成交量8,819
市值276.8B
Beta 值 (5 年,每月)0.29
市盈率 (最近 12 個月)17.88
每股盈利 (最近 12 個月)18.40
業績公佈日
遠期股息及收益率9.97 (3.05%)
除息日2022年3月17日
1 年預測目標價
  • Benzinga

    Kiniksa Inks Global License Agreement With Roche For Vixarelimab

    Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) has announced a global license agreement with Roche Holdings AG (OTC: RHHBY) and Genentech to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta. "The agreement provides an optimal infrastructure for the further development of vixarelimab. We plan to allocate the non-dilutive capital from this transaction towards synergistic opportunities across our portfolio, including expanding our ARCALYST ca

  • Benzinga

    Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field

    Poseida Therapeutics Inc (NASDAQ: PSTX) has entered into a strategic collaboration and license agreement with Roche Holdings AG (OTC: RHHBY), focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas, and other hematologic indications. Under the agreement, Roche will receive from Poseida either exclu

  • Benzinga

    Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit

    Roche Holdings AG's (OTC: RHHBY) 1H FY22 sales reached CHF 32.3 billion, +5% Y/Y on higher sales of diagnostic tests and pharmaceuticals. Core operating profit increased 9% to CHF 12.7 billion, and EPS up 11% to CHF 11.76. Ocrevus revenue increased 17% to reach CHF 2.9 billion, and Hemlibra sales jumped 30% to CHF 1.83 billion, offsetting a decline in established off-patent cancer medicines Herceptin, Avastin, and Rituxan due to cheaper rival products. Arthritis med Actemra/RoActemra sales decli